



REFERENCES

- 1) **Aarabi B, Haghsheenas M and Ra keii V. (1998):** Visual failure caused by suprasellar extramedullary hematopoiesis in beta thalassemia: case report. *Neurosurgery*; 42:922–925.
- 2) **Aessopos A (2009).** Cardiac function and iron chelation in thalassemia major and intermedia: a review of the underlying pathophysiology and approach to chelation management *Medit J Hemat Infect Dis* www.MJHID.org Advance online publication 18.09.
- 3) **Aessopos a, ,Farmakis D,Tsironi M,Deftereos S,Polonifi A,Moyssakis I,et al(2005).** Cardiovascular effects of splenomegaly and splenectomy in b thalassemia .*Ann Hematol*; 84:353-357.
- 4) **Aessopos A, Deftereos S, Farmakis D, et al.(2004)** Cardiovascular adaptation to chronic anemia in the elderly: an echocardiographic study. *Clin Invest Med.*; 27:265-273.
- 5) **Aessopos A, et al.(2007).** Predictive echo-Doppler indices of left ventricular impairment in B-thalassemic patients. *Ann Hematol.*; 86:429–34.
- 6) **Aessopos A, Farmakis D, Hatziliami A, et al. (2004).**Cardiac status in well treated patients with thalassemia major. *Eur J Haematol.*; 73(5): 359-366.
- 7) **Aessopos a, farmakis d, karagiorga m, voskaridou e, loutradi a, hatziliami a, joussef j, rombos j, loukopoulos D (2001):** cardiac involvement in thalassemia intermedia: amulticenter study. *Blood* 97:3411–3416
- 8) **Aessopos A, Farmakis D. (2005).** Pulmonary hypertension in beta-thalassemia. *Ann N Y Acad Sci.*; 1054:342-349.
- 9) **Aessopos A, Stamatekis G, Skoumas V, Vassilopoulos G, Mantzourani M, Loukopoulos D.(1995).** Pulmonary hypertension and right heart failure in patients with b-thalassemia intermedia. *Chest*; 107:50–53.



References

- 10) **Aessopos A, Farmakis D, Tsironi M, Deftereos S, Tassiopoulos K, et al (2004).** Hemodynamic assesement of splenomegaly in B thalassemic patients undergoing splenectomy .Ann Hematol; 83:775-778.
- 11) **Aessopos A. (2004).** Cardiovascular adaptation to chronic anemia in the elderly: an echocardiographic study. Clin Invest Med.; 27:265–73.
- 12) **Aessopos A. (1997).** Cardiac magnetic resonance imaging R2* assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia. Haematologica. 2007; 92:131–2.
- 13) **Aessopos A. (2007).** Correlation of echocardiography parameters with cardiac magnetic resonance imaging in transfusion-dependent thalassaemia major. Eur J Haematol.; 78:58–65.
- 14) **Aessopos A. (2008).** Plasma B-type natriuretic peptide concentration in beta-thalassaemia patients. Eur J Heart Fail. 9:537–41.
- 15) **Aggeli C, Antoniadis C, Cosma C, et al. (2005).** Endothelial dysfunction and inflammatory process in transfusion-dependent patients with beta-thalassemia major. Int J Cardiol.;105:80-84.
- 16) **Allen SJ, O'Donnell A and Alexander ND. (1997):** alpha⁺-Thalassemia protects children against disease caused by other infections as well as malaria. Proc Natl Acad Sci U S A; 94:14736–14741.
- 17) **Amer J and Fibach E. (2004):** Oxidative status of platelets in normal and thalassemic blood. Thromb Haemost; 92:1052-9.
- 18) **Anderson LJ, Holden S, Davis B, et al. (2001).** Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001; 22:2171-2179.
- 19) **Anderson LJ, Westwood MA, Holden S, et al. (2004).** Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol.;127:348-355.
- 20) **Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM and Pennell DJ. (2002):** Comparison of effects of oral deferiprone and



References

- subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassemia. *Lancet*; 360: 516-20.
- 21) **Angastiniotis M and Modell B. (1998):** Global epidemiology of hemoglobin disorders. *Ann N Y Acad Sci*; 850:251-9.
- 22) **Angelucci E, Bai H and Centis F. (2002):** Enhanced macrophagic attack on β -thalassemia major erythroid precursors. *Haematologica*; 87:578-83.
- 23) **Angelucci E.(2000).** Hepatic iron concentration and total body iron stores in thalassaemia major. *N Engl J Med.*; 343:327–31.
- 24) **Atichartakarn V,Likittanasombat K,Chuncharunee S,chandanammatttha P,Worapongpaiboon S,(2003).** Pulmonary arterial hypertension in previously splenectomized patients with b thalassemiac disorders .*Int J Hematol* 2003; 78:139-45.
- 25) **Atiq M,Bana M,Ahmed US,Bano S,Yousef M,Fadoo Z,et al(2006).** Cardiac disease in beta –thalassemia major:is it reversible?Singapore Medical Journal;47(8):693-6.
- 26) **Atweh GF and Loukopoulos D. (2001):** Pharmacological induction of fetal hemoglobin in sickle cell disease and b-thalassemia. *Semin Hematol*; 38:367-73.
- 27) **Au WY, Lam WW, Chu W, et al., (2008).** A T2* magnetic resonance imaging study of pancreatic iron overload in thalassemia major. *Haematologica*. 93:116-119.
- 28) **Bahal VK,Malhotra OP,Kumar D,Agarwal R.,et al (1992).**Non-Invasive assesment of systolic and diastolic LV functions with chronic sever anemia:*Am Heart J* 124:1516-1523.
- 29) **Baker DW, Chin MH, et al (2001).** ACC\AHA guidelines for evaluation and management of chronic heart failure in adults: 1-56.
- 30) **Banerjee P, Banerjee T, Khand A et al., (2002).** Diastolic heart failure: neglected or misdiagnosed: *J Am Coll Cardiol* 39(1)138-141.
- 31) **Benz EF and Giardina PTV (1995):** Thalssemia syndromes. In: Blood disease of infancy and childhood Miller DR and Bachner RL (Eds) seventh Edition Mosby year book, p.160.



References

- 32) **Berdoukas V. (2005).** Lack of correlation between iron overload cardiac dysfunction and needle liver biopsy iron concentration. *Haematologica*. 90:685–6.
- 33) **Berger M, Haimowitz A, Van Tosh A, Berdoff RL, Goldberg E. (1985).** Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. *J Am Coll Cardiol*; 6:359-365.
- 34) **Beris P (1995):** Thalassemia management. *Semin Hematol*; 32: 243-313.
- 35) **Bhanu NV, Trice TA, Lee YT and Miller JL. (2004):** A signaling mechanism for growth-related expression of fetal hemoglobin. *Blood*; 103:1929-33.
- 36) **Bhatia RS, Tu JV, Leeds Et Al., (2006).** Outcome of heart failure with preserved ejection fraction in a population based study. *N. Engl. J Med* .355(3):260-9.
- 37) **Bircher J. (1999).** Rodes – Editors Oxford Textbook of Clinical Hepatology. 2. Vol. 2. New York: Oxford Univ Press;. 1862.
- 38) **Bleeker GB, Steendijk P, Holman ER, Yu C-M, Breithardt O, Kaandorp T. (2006).** Assessing right ventricular function :the role of echocardiography and complementary technologies heart ;92:19-26.
- 39) **Borenstain-Ben Yashar V, Barenholz Y, Hy-Am E, et al (1993)..** Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. *Am J Hematol*. 1993; 44(1):63-65.
- 40) **Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. (2006).** Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. *Blood*.;107:3733-3737
- 41) **Borgna-Pignatti C, et al. (2004).** Survival and complications in patients with thalassemia major treated with transfusion and desferrioxamine. *Haematologica*. 89:1187–93.]
- 42) **Bosi G, Crepaz R, Gamberini MR, Fortini M, Scarcia S, Bonsanate E et al. (2003).** Left ventricular remodeling and systolic and diastolic function in young adults with b-thalassemia major: a Doppler



References

- echocardiographic assessment and correlation with haematological data. *Heart*;89:762–6
- 43) **Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de and Montalembert M. (2003):** Hydroxyurea can eliminate transfusion requirements in children with severe β -thalassemia. *Blood*; 102: 1529-30.
- 44) **Braude P, Pickering S, Flinter F and Ogilvie CM. (2002):** Preimplantation genetic diagnosis. *Nat Rev Genet*; 3:941-53.
- 45) **Braunwald E (2001)** Heart disease, 6th edn. W.B. Saunders, Philadelphia, pp 2226–2227
- 46) **Campillini MD (2007)..**Guidelines for the clinical management of thalassemia .Thalassemia International federation .2 nd ed, 1-250.
- 47) **Cappellini MD, Cohen A, Piga A, et al.(2006).** A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. *Blood*. 107:3455-3462.
- 48) **Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, and Mannucci AP. (2000):** Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. *Br J Haematol*; 111:467-73.
- 49) **Caramuru LH, Soares Rde P, Maeda NY, Lopes AA.(2003).** Hypoxia and altered platelet behavior influence von Willebrand factor multimeric composition in secondary pulmonary hypertension. *Clin Appl Thromb Hemost.*;9(3):251-258.
- 50) **Caterina BP and Renzo G (2004):** Thalassemias and Related Disorders: Quantitative Disorders of Hemoglobin Synthesis. In: *Wintrobe's Clinical Hematology*. Chapter 42 John P. Greer, John Foerster, John N. Lukens, George M. Rodgers, Frixos Paraskevas, and Bertil Glader (eds). Lippincott Williams & Wilkins, pp 1052-1075.
- 51) **Cazzola M. Barella S. (1995).** Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major. *Br J Haematol*. 89:473–8.



References

- 52) **Cazzola M.(1983).** Internal distribution of excess iron and sources of serum ferritin in patients with thalassemia. Scand J Haematol.; 30:289–96.
- 53) **Ceci A, Baiardi P and Felisi M. (2002):** The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol; 118:330-6.
- 54) **Centis F, Tabellini L and Lucarelli G. (2000):** The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with β -thalassemia major. Blood; 96:3624-9.
- 55) **Chao TH and Wang B (1996):** The correlation of serum ferritin to Ca/p metabolisms and bone density study in thalassemic patients. J Pediatr Endocrinol Metab., 9(6):809-4.
- 56) **Chapman RW. (1982).** Effect of ascorbic acid deficiency on serum ferritin concentration in patients with beta-thalassaemia major and iron overload. J Clin Pathol.; 35:487–91.
- 57) **Choudhry VP.(1997).** Hematopoietic stem cell transplantation .Indian Pediatr; 34:505-17.
- 58) **Cighetti G, Duca L and Bortone L. (2002):** Oxidative status and malondialdehyde in b-thalassemia patients. Eur J Clin Invest; 32: Suppl 1:55-60.
- 59) **Cohen AR, Galanello R and Pennell DJ. (2004):** Thalassemia. Hematology (Am Soc Hematol Educ Program); 14-34
- 60) **Cooper C, Landzberg M, Anderson T, et al (1996).** Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. Circulation. 93:266-271.
- 61) **Cunningham MJ, Macklin EA, Neufeld EJ and Cohen AR. (2004):** Complications of β -thalassemia major in North America. Blood; 104:34-9.
- 62) **Davis BA.(2004).** Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood. 104:263–9.



References

- 63) **Davis BA.(2000).** Long-term outcome of continuous 24-hour desferrioxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. *Blood*. 95:1229–36.
- 64) **Dawson SB and Trapp R (1994):** Basic and clinical biostatistics in: Lange Medical Book 2nd edition, prentice – Hall International Inc; 201-205.
- 65) **De Baun MR, Vichins E .Hemoglobinopathies .Kliegman MR, behrmaner ,Stanon BF ,Jenson BH. (2008)** Nelson Textbook of Pediatrics, 18 Th ed Philadelphia ,Saunders.Elsevier :4(462)2025-36.
- 66) **De Sanctis V. (2002):** Growth and puberty and its management in thalassaemia. *Horm Res*; 58: Suppl 1:72-9.
- 67) **Deem S, Kim JU, Manjula BN, et al.(2002).** Effects of S-nitrosation and cross-linking of hemoglobin on hypoxic pulmonary vasoconstriction in isolated rat lungs. *Circ Res*;91:626–632.
- 68) **Derchi G,Forni GL,Formisano F ,et al(2005)** .Efficacy and safety of sildenafil in the treatment of sever pulmonary hypertension in patients with hemoglobinopathies .*Haematologica* .;90(4):452-458.
- 69) **Di Naro E, Ghezzi F and Vitucci A. (2000):** Prenatal diagnosis of b-thalassemia using fetal erythroblasts enriched from maternal blood by a novel gradient. *Mol Hum Reprod*; 6:571-4.
- 70) **Ding C, Chiu RWK and Lau TK. (2004):** MS analysis of single-nucleotide differences in circulating nucleic acids: application to noninvasive prenatal diagnosis. *Proc Natl Acad Sci USA*; 101 :10762-7.
- 71) **Du zd, roguin n, milgram e, saab k, koren a. (1997).** Pulmonary Hypertension in patients with thalassemia major. *Am heart* ;134:532–537.
- 72) **Eaton JW.Qian M.(2002).** Mollecular bases of cellular iron toxicity .*free Radic Biol Med*:32:833-40.
- 73) **El –Gowhary s,AL –Shafie S ,Niazi M ,Aziz M,El –Beshlawy A.(2007).** Study of B thalassemia mutations using PCR Amplification refractory mutations system and direct DNA sequencing techniques in group of Egypton Pediatrics ,Hemoglobin .:31 (1):195 -7.



References

- 74) **El-Beshlawy A (2005):** Highlights on prevention and clinical issue on thalassemia management in Egypt, sixth International Conference, Update in Thalassemia (From prevention to gene therapy, Cairo,Egypt,p 21-22.
- 75) **Eldor A and Rachmilewitz EA. (1999):** Coagulation study state in thalassemia. Blood; 91:362-44.
- 76) **Eldor A, Lellouche F and Goldfarb A. (1991):** In vivo platelet activation in beta-thalassemia major reflected by increased platelet-thromboxane urinary metabolites. Blood;77:1749–1753.
- 77) **Eldor A, Rachmilewitz EA. (2002).**The hypercoagulable state in thalassemia. Blood.;99(1):36-43.
- 78) **Emery DW, Yannaki E, Tubb J, nishinot, Li Q and Stamatoyannopoulos G. (2002):** Development of virus vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo. Blood; 100:2012-9.
- 79) **Fairbanks VF and Beutler E (1995):** Iron metabolism.In:William Hematology, Beutler E., Lichtman MA and Collar BS (eds), fifth edition , mcgraw –Hill Publishing company, New York pp, 369-380 .
- 80) **Fang J, Huang S and Chen C. (2004):** Umbilical cord blood transplantation in Chinese children with beta-thalassemia. J Pediatr Hematol Oncol;26:185-9.
- 81) **Farber HW, Loscalzo J.(2004).** Pulmonary arterial hypertension. N Engl J Med.;351:1655-1665.
- 82) **Farmakis D, Giakoumis A, Polymeropoulos E, Aessopos A.(2003).** Pathogenetic aspects of immune deficiency associated with beta-thalassemia. Med Sci Monit.;9:RA19-22.
- 83) **Farmakis D, Vesleme V, Papadogianni A, Tsiftaris P, Kapralos P, Aessopos A(2004).** Aneurysmatic dilatation of ascending aorta in a patient with beta-thalassemia and a pseudoxanthoma elasticum-like syndrome. Ann Hematol. ;83:596-599.



References

- 84) **Feigenbaum H, Armstrong WF, Ryan T. (2004).** Left atrium ,right atrium, right ventricle. In: Feigenbaums Echocardiography 6th ed . Wolter Kuler Lippincott William & Wilkines, 2004; 7: 202-10.
- 85) **Feigenbaum, Harvey; Armstrong, William F.; Ryan, Thomas (2005).** Feigenbaum's Echocardiography, 6th Edition, (3): 132.
- 86) **Ferrara M, Matarese SM, Francese M, et al. (2001).** Role of apolipoprotein E (APOE) polymorphism on left cardiac failure in homozygous beta thalassaemic patients. Br J Haematol.; 114: 959-960.
- 87) **Fibach E. (2001):** Cell culture and animal models to screen for promising fetal hemoglobin- stimulating compounds. Semin Hematol; 38: 374-81.
- 88) **Findlay JY, Harrison BA, Plevak DJ, Krowka MJ. (1999).** Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension. Liver Transpl Surg; 5: 381–387.
- 89) **Florea VG, Henein MY, Cicoira M et al., (2000).** Echocardiographic determinantsof mortality in patients >65 yrs old .Am J Cardiol: 86(2): 158-61.
- 90) **Forget BG (2000):** Thalassemia syndromes. In Hematology. Basic Principles and Practice. Hoffman R, Edward JB, Sanford JS et al. (Eds). 3rd edition. Churchill Livingstone. A Division of Harcourt Brace & Company. New York, Edinburgh, London Philadelphia, San Francisco, chapter 29, pp 486-506.
- 91) **Forget BG, Pearson HA (1995):** Hemoglobin synthesis and thalassemia, In Handin RI, Lux SE, Stossel TP. Blood principles and practice of hematology first ed., JB lippincott Company, Philadelphia, 1525.
- 92) **Forget BG. (2001):** Molecular genetics of the human globin genes. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, eds. Disorders of haemoglobin. Cambridge: Cambridge University Press.; 117–130.
- 93) **Franchini M and Veneri D. (2004):** Iron-chelation therapy: an update. Hematol J; 5: 287- 92.



References

- 94) **Freeman AP. (1983).** Early left ventricular dysfunction and chelation therapy in thalassaemia major. *Ann Intern Med.*;99:450–4.
- 95) **Fucharoen S and Winichagoon P. (2000):** Clinical and hematologic aspects of hemoglobin E beta-thalassemia. *Curr Opin Hemat*; 7: 106-112
- 96) **Ganavello R (1995):** Molecular basis of thalassemia major. *Int J Pediat Hematol Oncol.*;2:383-396.
- 97) **Ganz T. (2003):** Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. *Blood*;102:783-8.
- 98) **Gaziev J, Sodani P, polchi P, Andreani M, Lucarelli G (2005)..** Bone marrow transplantation in adults with thalassemia. Treatment and long term follow up. *Ann. N. Y. Acad. Sci.*;1054:196-205.
- 99) **Glader BE and Look KA. (1996).** Hematologic disorders in children from south east Asia. *Ped Clin N Am*;665-8.
- 100) **Grady R BV, Rachmielewitz EA, Giardina PJ. (2000).** Optimising chelation therapy: Combining deferiprone and deferoxamine. *Blood.*;96:604a,.
- 101) **Graziano JH and piomelli S. (1982).** A simple technique for preparation of young red cells for transfusion from ordinary blood units. *Blood*;59:865.
- 102) **Hahalis G, Manolis AS, Apostopouls D, (2002):** Right ventricular cardiomyopathy in Beta thalassemia major, *Eur, Heart J* 23:147-56.
- 103) **Hall JG, Martin PL, Wood S and Kurtzberg J. (2004):** Unrelated umbilical cord blood transplantation for an infant with beta-thalassemia major. *J Pediatr Hematol Oncol*;26:382-5.
- 104) **Hara S, Morishita R, Tone Y, et al. (1995).** Overexpression of prostacyclin synthase inhibits growth of vascular smooth muscle cells. *Biochem Biophys Res Commun* 1995;216:862–867.
- 105) **Hart CYT, Refield MM (2000).** Diastolic heart failure in community. *Curr cardiol reports* :2:461-469.
- 106) **Hassan M.Y (2001):** Thalassemia. *e Medicine J.* 2001; 2 (11): 1-42.
- 107) **Hassan M.Y (2007):** Thalassemia. *e Medicine J.* 2007 :1(132):1-65.



References

- 108) **Hershko C, Link G, Cabantchik I.(1998).** Pathophysiology of iron overload. *Ann N Y Acad Sci.* 1998;850:191-201.
- 109) **Hershko C, Link GM, Konijn AM and Cabantchik ZI. (2005):** Iron chelation therapy. *Curr Hematol Rep*;4:110-6.
- 110) **Higgs DR, Thein SL and Woods WG. (2001):** The molecular pathology of the thalassemias. In: Weatherall DJ, Clegg B, eds. *The thalassemia syndromes.* 4th ed. Oxford, England: Blackwell Science:133-91.
- 111) **Hoffbrand AV, Cohen A and Hershko C. (2003):** Role of deferiprone in chelation therapy for transfusional iron overload. *Blood*;102: 17-24.
- 112) **Hoffbrand AV, Pippard MJ. Iron .(1999).** IN: Hoffbrand AV, Lewis SM, Tuddenham EGD. *Postgraduate hematology .4 th ed.:*3:22-45.
- 113) **Honig GR, Galimberti M, Polchi P, Sharon BI, Harris PC(2000).** Thalassemia syndromes. In: Behrman RE, Kliegman RM, Jensen HB, eds. *Nelson Textbook of Pediatrics* 16th ed .Philadelphia: WB Saunders Company:1478-88.
- 114) **Hou JW. (1994).** Prognostic significance of left ventricular diastolic indexes in beta-thalassemia major. *Arch Pediatr Adolesc Med.*;148:862–6.
- 115) **Hovav T, Goldfarb A and Artmann G. (1999):** Enhanced adherence of β -thalassemia erythrocytes to endothelial cells. *Br J Haematol*;106:178–181.
- 116) **Hughes-Jones NC.(1984).** Thalassemias .In: *Lectures notes on hematology .4th ed .Oxford:Blackwell Scientific Publications.*;87-113.1
- 117) **Ignarro LJ.(1989).** Heme-dependent activation of soluble guanylate cyclase by nitric oxide: regulation of enzyme activity by porphyrins and metalloporphyrins. *Sem Hematol.*;26:63-76.
- 118) **Imren S, Fabry ME and Westerman KA. (2004):** High-level beta-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells. *J Clin Invest*;114:953-62.
- 119) **Jessup M, Manno CS.(1998).** Diagnosis and management of iron induced heart Disease in Cooley, sanemia. *Ann N Y Acad Sci*:850:242-250.



References

- 120) **Jimmy PS, Kai HL and Meng Yao LU (2001):** Abnormal glucose tolerance in transfusions-Dependent B thalassemia patients. *Diabetes Care* 24:850-854.
- 121) **Kattamis C. (1987).** Iron Overload and Chelation in Thalassemia. Bern: Hans Huber Publishers;.
- 122) **Kazazian HH and Bochm CD. (1988).** Molecular basis and prenatal diagnosis of B-thalassemia .*Blood*;72:1107-16.
- 123) **Kazazian HH (1990):** The thalassemia syndromes, molecular basis and prenatal diagnosis. *Semin Hematol.*,27:209-11.
- 124) **Khalaf MR .(1991).** Hemoglobin pattern in B-thalassemia trait .*Egypt J Hematol*;61:107-114.
- 125) **Khalifa AS ,Baffico M, Hesmat NM, et al.(1995):** Relationship between the hematological phenotype and the type of beta-thalassemia mutation in Egyptian children. *Egypt J Hematol.*,20(2):130-137.
- 126) **Khalifa AS, Salem M, Mounir E, El-Tawil MM, El-Sawy M and Abd Al-Aziz MM (2004):** Abnormal glucose tolerance in Egyptian beta-thalassemic patients: Possible association with genotyping. *Pediatr Diabetes*; 5: 126-132.
- 127) **Khalifa AS, Fattah SA, Maged Z, Sabri F. Mohamed HA .(1983).** T cell functions in infants and children with B thalassemia .*acta Hematol*;69:139-44.
- 128) **Khalifa AS, Maged Z, Khalil R, Sabri F, Hassan O, El-Alfy M.(1988).** immunoglobulins level, Opsonic activity and phagocytic power in Egyption thalassemic children. *Acta Hematol*;79:153-6.
- 129) **Kimball TR, Michelfelder EC, Echocardiography. Allan HD, Driscoll DJ, Shaddy RE, Feltes TF (2008).** .In: Moss and Adams heart diseases in infants ,children and adolescents including fetuses and young adults 7th ed .Wolter Kuler Lippincott William&Wilkinnes,;(6):96-163.
- 130) **Kircher BJ, Himelman RB, Schiller NB.(1990).** Non invasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava .*am J cardiol* 1990;66:493-496.



References

- 131) **Kontoghiorghes GJ. (2006).** Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAlI and starch deferoxamine polymers. *Hemoglobin*.;30:329-347.
- 132) **Kremastinos DT, Tsiapras DP, Tsetsos GA, Rentoukas EI, Vretou HP, Toutouzas PK, (1993).** Left ventricular diastolic Doppler characteristics in beta thalassemia major. *circulation*. 1993;88(3): 1127-35.
- 133) **Kurteber J, Laughlin M, Graham ML, Smith C, Olsan JF, Halperin EC. (1996).** Placental blood as a source of hematopoietic stem cell for transplantation into unrelated recipients. *N Engl J Med*;335:157-66.
- 134) **Kuypers FA and de Jong K. (2004):** The role of phosphatidylserine in recognition and removal of erythrocytes. *Cell Mol Biol*;50:147-58.
- 135) **Lacerra G, Sierakowska H and Carestia C. (2000):** Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. *Proc Natl Acad Sci USA*;97:9591-6.
- 136) **Lainchbury JG, Refield MM. (1999).** Doppler echocardiographic guided diagnosis and therapy of heart failure. *Curr Cardiol reports* ;1:55-66.
- 137) **Lang I, Kerr K, (2006).** Risk factors for chronic thromboembolic pulmonary hypertension. *Proc Am Thorac Soc* 2006;3:568-70.
- 138) **Lanzkowsky P. Hemolytic anemia (1989)..** In: *Manual of pediatric hematology and oncology*. 1st Ed. London :Churchill Livingstone;97-152.
- 139) **Lee SL, Wang WW, Lanzillo JJ, et al. (1994).** Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. *Am J Physiol*;266:L46– L52.
- 140) **Lekawanvijit S, Chattipakorn N. (2009).** Iron overload thalassemic cardiomyopathy: iron status assessment and mechanisms of mechanical and electrical disturbance due to iron toxicity. *Can J Cardiol*;25:213-218.
- 141) **Lesic B, Foulon J, Carniel E. (2002).** Comparison of the effects of deferiprone versus deferoxamine on growth and virulence of *Yersinia enterocolitica*. *Antimicrob Agents Chemother*.;46:1741-1745.



References

- 142) **Lin MJ, Leung G, Zhang WM, et al.(2004).** Chronic hypoxia-induced upregulation of store-operated and receptor-operated Ca² channels in pulmonary arterial smooth muscle cells: a novel mechanism of hypoxic pulmonary hypertension. *Circ Res*; 95:496–505.
- 143) **Loasombaty V, Giardina OJ, Omri LL et al., (2001):** Clinical and Hematological features of codon 17.Mutation of beta thalassemia. *Eur J Haematol.*, 66(2):126-9.
- 144) **Locatelli F, Rocha V and Reed W. (2003):** Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. *Blood*;101:2137-43.
- 145) **Louise LO and Singer ST (2002):** Thalassemia :current approach to an old disease.*Hematol Oncol Pediatr. Clin N Am., Pediatr, Part II* 49(6): 1278-1303.
- 146) **Lucarelli G, Galimberti M and Polchi P. (1993):** Bone marrow transplantation in patients with thalassemia responsive to iron chelation therapy. *N Engl J Med*; 329(12): 840-845.
- 147) **Lucarelli G, Galimberti M, Polchi P.(1996).** Bone marrow transplantation for patients with thalassemia :Result in class 3 patients .*Blood* 1996;87:2062-88.
- 148) **Lukens TN (1993):** The thalassemia and related disorders in wintrob's clinical hematology, ninth edition : Lee GR, Brithhell TC, Forester J, Athens JW and Lukens JN (eds),Harcourt Health Science, Philadelphia; pp:1102-1105.
- 149) **Lukens TN (1999):** The thalassemia and related disorders. Quantitative disorders of hemoglobin synthesis. In : wintrob's clinical hematology.Richard G, John F,Frixos P et al. (eds), tenth edition, volume 1, Philadelphia WB Saunders,pp. 1405-1446.
- 150) **Malik P and Arumugam PI (2005):** Gene Therapy for {beta}-Thalassemia. *Hematology (Am Soc Hematol Educ Program)* 2005; 45-50
- 151) **Mandell MS, Groves BM. (1996).** Pulmonary hypertension in chronic liver disease. *Clin Chest Med*;17:17. 446 Case Report: Tam and Farber
American Journal of Hematology DOI 10.1002/ajh



References

- 152) **Manodori AB, Barabino GA, Lubin BH, et al.(2000).** Adherence of phosphatidylserine- exposing erythrocytes to endothelial matrix thrombospondin. *Blood.*; 95(4):1293-1300.
- 153) **Mc Mahon CJ, Nagueh SF, Eapen RS, et al (2005)..** Echocardiographic predictors of adverse clinical events in children with dilated cardiomyopathy: a prospective clinical study .*Heart*; 90:908-15.
- 154) **Mcdaniel SS, Platoshyn O, Wang J, et al. (2001).** Capacitative Ca² entry in agonist-induced pulmonary vasoconstriction. *Am J Physiol Lung Cell Mol Physiol*;280:L870–L880.
- 155) **Mclaughlin VV, Genthner DE, Panella MM, Rich S. (1998).** Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. *N Engl J Med* 1998;338:273–277.
- 156) **Mehra N K.(1997).** Asian Indian Donor Marrow Registry.In:Proceedings of 2nd Natonal thalassemia conference .New Delhi;58-60.
- 157) **Meluzin J,Spinarova L,Bakala J,Toman J,Krejci J,Hude P(2001),.** Pulsed Doppler tissue imaging of the velocity of tricuspid annular systolic motion ;a new rapid ,and non invasive method of evaluating right ventricular systolic function .*Eur Heart J. Feb*;22(4):340-8.
- 158) **Miskin H,Yaniv I,Berant M,Hershko C.(2003).** Reversal of cardiac complication in thalassemia major by long term intermittent daily intensive iron chelation *Eur J Hematol* 2003;70:398-403.
- 159) **Michael J et al .,(2005):**Diastolic dysfunction in adults :4-56.
- 160) **Modell B ,Darlison M(2008).** Global epidemiology of hemoglobin disorders and derived service indicators .*Bulletin of the WHO* 86: (6) 480-7.
- 161) **Modell B, Khan M and Darlison M. (2000):** Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. *Lancet*;355:2051-2.
- 162) **Modell B. (1984).**The Clinical Approach to Thalassaemia. New York: Grune and Stratton;. Pp. 165–9.



References

- 163) **Moncada S, Higgs A. (1993).** The L-arginine-nitric oxide pathway. *N Engl J Med*;329:2002-2012.
- 164) **Moratelli S, De Sanctis V and Gemmati D. (1998):** Thrombotic risk in thalassemic patients. *J Pediatr Endocrinol Metab*;11[Suppl 3]:915–921.
- 165) **Moratelli S, De Sanctis V, Gemmati D, et al. (1999).**botic risk in thalassemic patients. *J Pediatr Endocrinol Metab*;11 Suppl 3:915-921.
- 166) **Moreau-Gaudry F, Xia P and Jiang G. (2001):** High-level erythroid-specific gene expression in primary human and murine hematopoietic cells with self-inactivating lentiviral vectors. *Blood*; 98: 2664-72.
- 167) **Morris C, Kuypers F, Kato G, et al.(2005).** Hemolysis-associated pulmonary hypertension in thalassemia. *Ann NY Acad Sci*; 1054:481-485.
- 168) **Morris CR, poljakovic M, Kato G, et al.(2005).** Dysregulated arginine metabolism, hemolysis associated pulmonary hypertension and mortality in sickle cell disease .*JAMA*; 294:81-90.
- 169) **Morris CR, Singer ST, Walters MC.(2006)** Clinical hemoglobinopathies: iron, lungs and new blood. *Curr Opin Hematol*; 13(6):407-418.
- 170) **Morris CR, Morris SM, Jr., Hagar W, et al (2003).** Arginine therapy: a new treatment for pulmonary hypertension in SCD? *Am J Respir Crit Care Med* ;168:63-69.
- 171) **Morris CR. (2006):** New strategies for the treatment of pulmonary hypertension in sickle cell disease: the rationale for arginine therapy. *Treat Respir Med*;5(1):31-45.
- 172) **Morsy MF,Alnajar AA ,Almuzainy IS,Alhawsawi ZM,Alsera MH,Ahmed AA (2008):** ,splenectomized versus non splenectomized patients with B thalassemia major ,Echocardiographic comparisons .*Saudi Med J* 2008 ;29:1310-4.
- 173) **Murray JF, Dawson AM, Sherlock S. (1958).**Circulatory changes in chronic liver disease. *Am J Med*. 1958;24:358-367.
- 174) **Nemeth E, Ganz T. (2006).** Hcpidin and iron-loading anemias. *Haematologica*;91:727-732.



References

- 175) **Nicolaides KH and Rodeck CN.(1985).** Obstetric management and diagnosis of hematologic diseases in fetus. *Clinics in Hematology*;14:775-801.
- 176) **Nienhuis AW.(1981).** Vitamin C and iron. *N Engl J Med.*;304:170-171.
- 177) **Oivieri NF and Koren G.(1990).** Studies of the oral chelator 1,2 dimethyl 3- hydroxyoyrid -4-one of thalassemic patients .*Semin Hematol*;27:101-7.
- 178) **Old JM, Olivieri NF and Thein SL. (2001):** Diagnosis and management of thalassemia. In: Weatherall DJ, Clegg B, eds. *The thalassaemia syndromes*. 4th ed. Oxford, England: Blackwell Science: 630-85.
- 179) **Olivieri NF ,Sharama S,Desilva S.(1999).** Impact of a low transfusion regimen on growth and iron loading in hemoglobin E/B-thalassemia blood;94:422a.
- 180) **Olivieri NF. (1994):** Medical progress: The β -thalassemias. *N Engl J Med*;34:99.
- 181) **Olivieri NF.(1997).** Iron-chelating therapy and the treatment of thalassemia. *Blood.*;89:739–61.
- 182) **Olivieri NF.(1997):** Thalassemia. Recent advances in *Pediatrics*;15:53:68.
- 183) **Olschewski H, Seeger W.(2002).** Pulmonary hypertension: Pathophysiology, diagnosis, treatment, and development of a pulmonaryselective therapy. Bremen, Germany: UNI-MED Verlag AS; p 27–38.
- 184) **Onerci M,Aslan S,Gumbruk F.(1994).** Audiologic and impedancemetric findings within thalassemia patients .*Inter J Pediatr otorhino*;28:117-22.
- 185) **Origa R. (2005).** Combined therapy with deferiprone and desferrioxamine in thalassemia major. *Haematologica*;90:1309–14.
- 186) **Oslon Lj,Edwards wd,mccall JT.(1987).** Cardiac iron deposition in idiopathic haemochromatosis;histologic and analytic assesement of 14 hearts from autopsy.jam Coll Cadio:123-43.



References

- 187) **Otto CM (2000).** Echocardiographic evaluation of left and right ventricular systolic function .textbook of clinical echocardiography second ,Philadelphia (PA):WB Saunders ;p.100-128.
- 188) **Owan TE,Hodge DO et al .,(2006).** Trends in prevalence and outcome of heart failure with preserved ejection fraction.N.Engl>J.Med .355(3):251-9.
- 189) **Pace BS, Shartava A, Pack-Mabien A, Mulekar M, Ardia A and Goodman SR. (2003):** Effects of N-acetylcysteine on dense cell formation in sickle cell disease. Am J Hematol; 73:26-32.
- 190) **Papanikolaou G, Tzilianos M and Christakis JI. (2005):** Hepcidin in iron overload disorders. Blood;105:4103-5.
- 191) **Parkes JG, Liu Y,Sirna JB.(2000).** Changes in gene expression with iron loading and chelation in cardiac myocytes and non myocytic fibroblast .J mol Cell cardiol:32:233-46.
- 192) **Pellerin D,Sharma R,Elliott P,Veyrat C.(2003).** Tissue Doppler,Strain and strain rate echocardiography for assesment of left and right systolic ventricular function.Heart;(1)69-75.
- 193) **Pennell DJ, Berdoukas V, Karagiorga M, et al.(2006).** Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood.;107:3738-3744.
- 194) **Persons DA and Nienhuis AW. (2003):** Gene therapy for the hemoglobin disorders. Curr Hematol Rep;2:348-55.
- 195) **Phrommintikul A,Sukonthasam A,Kajananvit R,Nawarawong W.(2006).** Splenectomy a strong risk factors for pulmonary hypertension in patients with B thalassemia .Heart ;92:1467-72.
- 196) **Piga A, Gaglioti C, Fogliacco E, Tricta F (2003)..** Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica.;88:489-496.
- 197) **Pinna AD.(1988).** Indications and results for splenectomy for beta thalassemia in two hundred and twenty-one pediatric patients. Surg Gynecol Obstetric.;167:109–13.



References

- 198) **Piomelli S,(2005).** The splenectomy controversy. *Ann NY Acad Sci* 2005;1054:511-513.
- 199) **Piomelli S, Buener CD, Lucarelli G (1989).** Cooley's anemia management: 25 years of progress. in *advances and controversies in Thalassemia Therapy .Bone marrow transplantation and other approaches.* New York, Alan R Liss 1989; 23-26.
- 200) **Piomelli S, Daneff SJ, Becker MH, Lipera MJ, Travis ST (1969).** Prevention of bone malformations and cardiomegaly in Cooley's anemia by early hypertransfusion regimen. *Ann NY Acad Sci*; 165: 427-36.
- 201) **Pootrakul P, Sirankapracha P and Hemsorach S. (2000):** A correlation of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in Thai patients with thalassemia. *Blood*; 96: 2606-12.
- 202) **Pootrakul P, Sirankapracha P and Sankote J. (2003):** Clinical trial of deferiprone iron chelation therapy in β -thalassaemia / haemoglobin E patients in Thailand. *Br J Haematol*; 122: 305-10.
- 203) **Porter JB, Jawson MS, Huchns ER.(1989).** Desferroxamine ototoxicity .evaluation of risk factors in thalassemic patients and guidelines for safe dosage .*Br.J Hematol*; 37: 403-9.
- 204) **Propper RD and Button LN (1980)..** New approaches to the transfusion management of thalassemia. *Blood*; 55: 55.
- 205) **Puthenveetil G and Malik P. (2004):** Gene therapy for hemoglobinopathies: are we there yet? *Curr Hematol Rep*; 3: 298-305.
- 206) **Puthenveetil G, Scholes J and Carbonell D. (2004):** Successful correction of the human β -thalassemia major phenotype using a lentiviral vector. *Blood*; 104: 3445-53.
- 207) **Quiones MA, Otto Cm, Stoddard M, Waggoner A, Zoghbi WA,(2002).** Doppler Quantification Task Force of the Nomenclature and standards Committee of American Society of Echocardiography. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task force of the Nomenclature and Standards Committee of the American Society of Echocardiography .*J Am Soc Echocardiogr* 2002; 15: 167-148.



References

- 208) **Quirolo k and Vinckinsky E (2004):** Hemoglobin disorders in Nelson textbook of pediatrics .Behrman R, Kleigman RM and Tenson, HB (eds) seventeenth ed., Philadelphia, London, Toronto, WB, Saunders,4(54):1623-1634.
- 209) **Rachmilewitz EA and Schrier SL. (2001):** Pathophysiology of β thalassemia. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, eds. Disorders of hemoglobin: genetics, pathophysiology, and clinical management. Cambridge: Cambridge University Press, pp:233–251.
- 210) **Rachmilewitz EA, Weizer-Stern O and Adamsky K. (2005):** Iron and oxidative stress in thalassemia: Eighth International Cooley's Anemia Symposium. Ann N Y Acad Sci;1054:1-6.
- 211) **Rady MS, Baffico M, Khalifa AS, Heshmat NM, el-Moselhy S, Sciarratta GV, Hussein IR, Temtamy SA and Romeo G. (1997):** Identification of Mediterranean beta-thalassemia mutations by reverse dot-blot in Italians and Egyptians. Hemoglobin; 21(1):59-69.
- 212) **Raiola G, Galati MC and De Sanctis V. (2003):** Growth and puberty in thalassemia major. J Pediatr Endocrinol Metab;16:Suppl 2:259-66.
- 213) **Refaie FN and Wonke B.(1992).** efficacy and possible adverse effects of iron chelator 1,2 –dimethyl -3-hydroxypyrid -4-one (L1) in thalassemia major .Blood;80:593-6
- 214) **Reiter C, Wang X, Tanus-Santos J, et al.(2002)** Cell-free hemoglobin limits nitric oxide bioavailability in sickle cell disease. Nat Med.;8:1383-1389.
- 215) **Rivella S and Sadelain M. (2002):** Therapeutic globin gene delivery using lentiviral vectors. Curr Opin Mol Ther;4:505-14.
- 216) **Rother RP, Bell L, Hillmen P, et al.(2005).** The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA.;293:1653-1662.
- 217) **Rubin LJ.(1997).** Primary pulmonary hypertension. N Engl J Med. 1997; 336:111-117.
- 218) **Rund D and Rachmilewitz EA. (2001):** Pathophysiology of α - and β -thalassemia: therapeutic implications. Semin Hematol;38:343-9.



References

- 219) **Rund D, Rachmilewitz E. (2005).** Beta-thalassemia. *N Engl J Med.* ;353:1135-1146.
- 220) **Safar ME, Levy BI, Struijker-Boudier H.(2003).** Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. *Circulation.*;107:2864-2869.
- 221) **Schiller NB,Shah PM,Crawford M,demaria A,Devereux R,Feighenbum H,et al(1989).** Recommendations for quantification of the left ventricle by two dimensional echocardiography .American Society of Echocardiography Committee on Standards ,subcommittee on quantification of two dimensional echocardiograms.*J Am Soc Echocardiogr* ;2:358-367.
- 222) **Schrrier SL and Angelucci E (2005):** New strategies in the treatment of the thalassemias. *Annu Rev Med*; 56: 157-71
- 223) **Seliem MA, AL-saad HI,Bou-Holaigh IH,Khan MN,Palileo MR.(2002).** Left ventricular diastolic dysfunction in congenital chronic anemias during childhood as determined by comprehensive echocardiographic imaging including acoustic quantification.*Eur J Echocardiogr* ;3(2):103-10.
- 224) **Senati S,Gumbruk F,Delbakhsh p,Blakanci F,Altay C,(1993).** Gall bladder pathology in pediatric B thalassemia patients .A prospective ultrasonographic study .*Pediatr Radiol*;23:357-9.
- 225) **Singer ST, Kuypers FA, Styles L, et al.(2006).** Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state. *Am J Hematol.* 2006;81(9):670-675.
- 226) **Singer ST, Sweeters N, Vichinsky EP, Wagner AJ and Rachmilewitz EA. (2003):** A dose-finding and safety study of darbepoietin alfa (erythropoiesis stimulating protein) for the treatment of anemia in patients with thalassemia intermedia. *Blood*;102:268a.abstract.
- 227) **Sonakul D, Fucharoen S.(1992).** Pulmonary thromboembolism in thalassemic patients. *Southeast Asian J Trop Med Public Health*; 23 Suppl 2:25-28.



References

- 228) **Sonakul D, Suwanagool P, Sirivaidyapong P, et al.(1988).** Distribution of pulmonary thromboembolic lesions in thalassemic patients. Birth Defects Orig Artic Ser.; 23(5A):375-84.
- 229) **Steinberg MH, Barton F and Castro O. (2003):** Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA;289:1645-51.
- 230) **Sultanov ML and Gadzhieva NM.(1992).**Ocular function in B-thalassemic patients .Vestick Ofthalamolgii;108:42-5.
- 231) **Swirsky DM.(1995).**Blood cell morphology in health and disease .In:Dacie SJV,Lewis SM.Practical hematology.8th ed .london:Churchill Livingstone.;895-1120.
- 232) **Tadmouri Go, Gulen RI.Deniz (2003):** the electronic database for B thalassemia mutations in Arab World.Saudi Med j2003 .24:11:1192-8.
- 233) **Tanner MA, et al.(2007).** A randomized, 134:532–537134:532–537placebo-controlled double-blind trial of the effect of combined therapy with desferrioxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation.;115:1876–84. Epub 2007 Mar 19.
- 234) **Tanner MA, Galanello R, Dessi C, et al(2006).** Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson.;8:543-547.
- 235) **Tanner MA, Galanello R, Dessi C, et al.(2008).** Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson.;10:12.
- 236) **Telfer PT. (2000).** Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol.;110:971–7.
- 237) **Tesoriere L, D’Arpa D and Butera D. (2001):** Oral supplements of vitamin E improve measures of oxidative stress in plasma and reduce oxidative damage to LDL and erythrocytes in β -thalassemia intermedia patients. Free Radic Res;34:529-40.



References

- 238) **Testa U. (2004):** Apoptotic mechanisms in the control of erythropoiesis. *Leukemia*; 18:1176-99.
- 239) **Thein SL (1998):** Beta thalassemia. *Baillieres Clin Haematol.*, 11(1): 91-129.
- 240) **Tohamy MK, Eissa A N, Dorry EL, Nasser M, Donia A, Ramzy S. (2003).** Prevalence of β thalassemia carrier among the Egyptian school students. *Scimed J* 2003;15,(4):1-13.
- 241) **Trinder D, Fox C, Vautier G, Olynyk JK. (2002).** Molecular pathogenesis of iron overload. *Gut*; 51:290-295.
- 242) **Tsironi M. (2005).** Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. *Eur J Haematol.*; 74:84–5.
- 243) **Vacek MM, Ma H, Gemignani F, Lacerra G, Kafri T and Kole R. (2003):** High-level expression of hemoglobin A in human thalassemic erythroid progenitor cells following lentiviral vector delivery of an antisense snRNA. *Blood*; 101:104-11.
- 244) **Van de Velde H, Georgiou I and De Rycke M (2004):** Novel universal approach for preimplantation genetic diagnosis of beta-thalassaemia in combination with HLA matching of embryos. *Hum Reprod*; 19:700-8.
- 245) **Vatanavicharn S, Atanakulchal M, Tunt –Awiroon M.(1983).** Iron absorption in patients with β thalassemia, β thalassemia disease and effect of splenectomy. *Acta Hematol*; 69:414-6.
- 246) **Vetter B, Neu-Yilik G, Kohne E et al. (2000):** Dominant β – thalassemia : a highly unstable Hemoglobin is caused by a novel 6Kb deletion of the β - globin gene, *British Journal of Hematology*, 108: 176-181.
- 247) **Vichinsky EP.(2004).** Pulmonary hypertension in sickle cell disease. *N Engl J Med*; 350:857–859.
- 248) **Voetsch B, Jin RC, Loscalzo J.(2004).** Nitric oxide insufficiency and atherothrombosis. *Histochem Cell Biol.*; 122(4):353-367.
- 249) **Vogel M. (2003).** Tissue Doppler echocardiography in patients with thalassaemia detects early myocardial dysfunction related to myocardial iron overload. *Eur Heart J.*; 24:113–9.



References

- 250) **Voskaridou E and Terpos E. (2004):** New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. *Br J Haematol*; 127:127-39.
- 251) **Voskaridou E, Douskou M and Terpos E. (2004):** Magnetic resonance imaging in the evaluation of iron overload in patients with β -thalassemia and sickle cell disease. *Br J Haematol*; 126:736-42.
- 252) **Voskaridou E, Kyrtsolis MC and Terpos E. (2001):** Bone resorption is increased in young adults with thalassaemia major. *Br J Haematol*; 112:36–41.
- 253) **Walker EM, Jr., Walker SM.(2000).** Effects of iron overload on the immune system. *Ann Clin Lab Sci.*; 30:354-365.
- 254) **Warner JG, Metzger DC, Kitzman DW DW, et al (1999).** Losartan improves exercise tolerance in patients with diastolic dysfunction. *J Am Coll Cardiol* 33:1567-1572.
- 255) **Watanabe M, Ono S, Tomomasa T, Okada Y, Kobayashi T, Suzuki T, Morikawa a.(2003).** Measurement of tricuspid annular diastolic velocities by Doppler tissue imaging to assess right ventricular function in patients with congenital heart disease. *Pediatr Cardiol J.* 2003;24(5):463-7.
- 256) **Weatherall DJ (1998):** Pathophysiology of thalassemia *Baillieres Clin Hematol.*, 11(1):127-96.
- 257) **Weatherall DJ and Clegg JB, Higgs DR and Wood WG (1995):** The hemoglobinopathies. IN: the metabolic and molecular basis of inherited disease. Vol.III ed. By Scriver CR, Beaud et al, Sly WS, Valle D, Stanbury JW, Wyngarden JB and Friedrickson DS. Seventh edition, mcgraw-Hill Inc., 503-9.
- 258) **Weatherall DJ and Clegg JB. (2001):** The Thalassaemia Syndromes. Oxford: Blackwell Science, 2001.
- 259) **Weatherall DJ. (2001):** Phenotype-genotype relationships in monogenic disease: lessons from the thalassemias. *Nat Rev Genet*; 2:245-55.



References

- 260) **Weiner M, and Kartpatkin M. (1978).** Cooley,s anemia :high transfusion regimen and chelating therapy ,results and perspective. *J Pediatr*;92:653.
- 261) **Westgren M, Ringden O, Eik-Nes S, Ek S, Anvert M, Brubakk AM. (1996).** Lack of evidence of permanent engraftment in utero fetal stem cell transplantation in congenital hemoglobinopathies. *Transplantation*; 61:1176-79.
- 262) **Westwood MA, Anderson LJ, Maceira AM, et al. (2007).** Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron. *J Magn Reson Imaging*. 2007; 25:1147-1151.
- 263) **Westwood MA. (2005).** Intercentre reproducibility of magnetic resonance T2* measurements of myocardial iron in thalassaemi. *Int J Cardiovasc Imaging (US)*.; 21:531–8.
- 264) **Wiener E, Wanachiwanawin W and Chinprasertsuk S. (1996):** Increased serum levels of macrophage colony-stimulating factor (M-CSF) in alpha- and beta-thalassemia syndromes: correlation with anaemia and monocyte activation. *Eur J Haematol*; 57:364–369.
- 265) **Wolfe L, Olivieri N, Sallan D, et al. (1985).** Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. *N Engl J Med*; 312:1600–1603.
- 266) **Wolman IJ and Ortalani M. (1969).** Some clinical features of cooley,s anemia patients are related to transfusion schedules. *Ann NY Acad Sci*;105:407.
- 267) **Wonke B, Wright C, Hoffbrand AV. (1998).** Combined therapy with deferiprone and desferrioxamine. *Br J Haematol*. 103:361-364.
- 268) **Wonke B. (1998):** Bone disease in β -thalassaemia major. *Br J Haematol*; 103:897–901.
- 269) **Wood JC, et al. (2005).** MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle-cell disease patients. *Blood*. 106:1460–5.
- 270) **Wood JC. (2003).** Myocardial iron loading in transfusion dependent thalassemia and sickle-cell disease. *Blood*. 2003; 103:1934–6.



References

- 271) **WU G, Morris M, Jr (1997).** Arginine metabolism: nitric oxide and beyond. *Biochem J.*; 336:1-17.
- 272) **Wu KH, Change JS, Su BH, Peng CT. (2000).** Tricuspid regurgitation in patients with B thalassemia major. *Ann Hematol*; 8:779-83.
- 273) **Xia Y, Dawson V, Dawson T, et al. (1996).** Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. *Proc Natl Acad Sci.*; 93:6770-6774
- 274) **Xiao W and Oefner PJ. (2001):** Denaturing high-performance liquid chromatography: a review. *Hum Mutat*; 17:439–474.
- 275) **Zakynthinos E. (2001).** Pulmonary hypertension, interstitial lung fibrosis, and lung iron deposition in thalassaemia major. *Thorax*; 56:737–739.
- 276) **Zhan Q, Guo J, Tang J, et al. (1999).** Alteration of the level of plasma calcitonin gene related peptide and endothelin-1 in liver cirrhosis. *Zhonghua Nei Ke Za Zhi*; 38:91–93.
- 277) **Zoueva OP and Rodgers GP. (2004):** Inhibition of beta protein 1 expression enhances betaglobin promoter activity and beta-globin mRNA levels in the human erythroleukemia (K562) cell line. *Exp Hematol*; 32:700-8.